AGMO (alkylglycerol monooxygenase) is a tetrahydrobiopterin-dependent enzyme that catalyzes the oxidative cleavage of O-alkyl bonds in ether lipids, particularly plasmanyl lipids and lyso-alkylglycerophospholipids 12. The enzyme is localized to the endoplasmic reticulum membrane and shows major expression in liver and white adipose tissue 3. AGMO functions as the sole known enzyme capable of breaking down alkylglycerols, working in conjunction with PEDS1 to maintain ether lipid homeostasis by regulating the balance between plasmanyl and plasmenyl lipid subclasses 4. Mechanistically, AGMO deficiency leads to moderate accumulation of plasmanyl and plasmenyl lipid species and affects the overall lipid composition beyond the ether lipid pool 15. The enzyme plays important roles in adipocyte differentiation, with knockdown experiments showing preferential accumulation of plasmalogen phospholipids and shifts toward longer, more polyunsaturated fatty acid chains in triacylglycerols 5. AGMO also modulates platelet-activating factor (PAF) production in macrophages by regulating cellular lyso-PAF levels 6. Clinically, AGMO expression and activity correlate with circulating cholesterol, triglycerides, and lipoprotein levels, suggesting systemic metabolic relevance 4. Genetic analyses have implicated AGMO variants in various human pathologies including type 2 diabetes, neurodevelopmental disorders, and cancer 2.